Friday, July 10, 2026
🇺🇸 FDA

pharma · Hypophosphatasia · Paroxysmal Nocturnal Hemoglobinuria

Alexion Europe SAS

Alexion Europe SAS clinical programs — 33 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
EU HQ
89 Employees
EMA registrant Type
Company details
Status
Public
HQ
EU
Employees
89
Programs
33
Drugs
40
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Alexion Europe SAS projects

33 ClinicalTrials.gov programs sponsored by Alexion Europe SAS.

Alexion Europe SAS has 33 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

33 programs

Clinical programs

  1. ALXN 2040, ALXN 2040

    Alexion Europe SAS

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  2. ALXN1210-DGF-321

    Alexion Europe SAS

    Delayed Graft Function after Kidney Transplantation

    phase 3 small molecule active

    1 trial

  3. ALXN1210-IgAN-320

    Alexion Europe SAS

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  4. ALXN1210-IgAN-325

    Alexion Europe SAS

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  5. ALXN1210-TMA-313

    Alexion Europe SAS

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy

    phase 3 small molecule active

    1 trial

  6. ALXN1720 Placebo Product, Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  7. ALXN1840

    Alexion Europe SAS

    Wilson Disease

    phase 3 small molecule terminated

    1 trial

  8. ALXN1850

    Alexion Europe SAS

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  9. ALXN1850 placebo product, ALXN1850

    Alexion Europe SAS

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  10. ALXN1850, ALXN1850 placebo product

    Alexion Europe SAS

    hypophosphatasia

    phase 3 small molecule active

    1 trial

  11. ALXN1850-HPP-303

    Alexion Europe SAS

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  12. ALXN2040-PNH-303

    Alexion Europe SAS

    Patients with Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  13. ALXN2220-ATTRCM-301

    Alexion Europe SAS

    Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

    phase 3 small molecule active

    1 trial

  14. AZP-3601-CLI-002

    Alexion Europe SAS

    Hypoparathyroidism

    phase 3 small molecule active

    1 trial

  15. Danicopan

    Alexion Europe SAS

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  16. Eculizumab

    Alexion Europe SAS

    Neuromyelitis Optica

    phase 3 small molecule terminated

    2 trials

  17. Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  18. Ravulizumab

    Alexion Europe SAS

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 mab completed

    2 trials

  19. SODIUM CHLORIDE , CAEL-101

    Alexion Europe SAS

    stage IIIa cardiac AL amyloidosis

    phase 3 small molecule active

    1 trial

  20. SODIUM CHLORIDE , CAEL-101

    Alexion Europe SAS

    Stage IIIb cardiac AL amyloidosis

    phase 3 small molecule active

    1 trial

  21. Ultomiris 300 mg/3 mL concentrate for solution for infusion

    Alexion Europe SAS

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    phase 3 small molecule active

    1 trial

  22. Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Alexion Europe SAS

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy(HSCT- TMA)

    phase 3 small molecule active

    1 trial

  23. ALXN 2040, Placebo matching ALXN2040

    Alexion Europe SAS

    Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

    phase 2 small molecule active

    1 trial

  24. ALXN 2050, ALXN2050 Placebo Tablets

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  25. ALXN1210-NEPH-202

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  26. ALXN2350-DCM-201

    Alexion Europe SAS

    BAG3 Mutation Associated Dilated Cardiomyopathy

    phase 2 small molecule active

    1 trial

  27. ALXN2420-Acro-201

    Alexion Europe SAS

    Acromegaly

    phase 2 small molecule active

    1 trial

  28. Alxn1920 placebo product, ALXN1920

    Alexion Europe SAS

    Primary Mebranous Nephropathy (PMN)

    phase 2 small molecule active

    1 trial

  29. Tarperprumig Placebo, Tarperprumig

    Alexion Europe SAS

    Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis

    phase 2 small molecule active

    1 trial

  30. Vialed Saline Placebo, ALXN2030

    Alexion Europe SAS

    Antibody-Mediated Rejection after Kidney Transplantation

    phase 2 small molecule active

    1 trial

  31. Danicopan

    Alexion Europe SAS

    Healthy

    phase 1 small molecule completed

    1 trial

  32. [14C]-Danicopan

    Alexion Europe SAS

    Healthy

    phase 1 small molecule completed

    1 trial

  33. AA-HPP-407

    Alexion Europe SAS

    HYPOPHOSPHATASIA

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Alexion Europe SAS have?

33 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.